COMPANY PROFILE

Imvax

Explore full profile

A biotechnology company which licenses Jefferson systemic cancer immunotherapy technology

Philadelphia, United StatesFounded 2015Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Imvax

Imvax is a biotechnology company focused on developing personalized immunotherapy treatments for patients with solid tumors. The company leverages its proprietary immuno-oncology platform to create therapies that use a patient's own tumor cells to induce a broad and durable immune response against cancer. Imvax primarily serves patients suffering from glioblastoma and other solid tumors, operating within the biopharmaceutical market. The business model centers on the development and commercialization of its lead product, IGV-001, which is currently in Phase 2b clinical trials. Imvax generates revenue through partnerships, grants, and future sales of its therapies upon regulatory approval. The company has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for IGV-001, highlighting its potential in treating life-threatening conditions. Imvax's leadership team brings decades of experience in biopharma development and commercialization, driving the company's mission to save lives through medical and scientific innovation.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Philadelphia, United States
Employees: 24
Open positions: None listed
Dealroom signal: 62.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jan 2025	$29M	$560M	Undisclosed	↗
LATE VCOther financing	May 2024	$35M	$140M	Undisclosed	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Imvax website traffic

Latest recorded traffic for Imvax is 3.4K monthly website visits, up 78.9% over the last three months. Imvax's team declined 4% over the past year.

Latest monthly visits3.4K 3-month web change+78.9% 1-year team growth-4%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational	3	$69M	$274M
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
PIPierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments	St. Louis, United States	Acquired
CICirinaAt Cirina we are pioneering products that detect cancer at its earliest stages and empower you to take action	New York City, United States	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational
TBToma BiosciencesDna-based cancer testing technology the company was incorporated in 2011 and is based in	Foster City, United States	Operational
OBOrionis BiosciencesPioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities	Waltham, United States	Operational
EIeTheRNA immunotherapiesMessenger RNA immunotherapies for cancer and infectious diseases	Antwerp, Belgium	Acquired